Marotel et al., 2020 - Google Patents

The two-faces of NK cells in oncolytic virotherapy

Marotel et al., 2020

Document ID
11690733589092765131
Author
Marotel M
Hasim M
Hagerman A
Ardolino M
Publication year
Publication venue
Cytokine & Growth Factor Reviews

External Links

Snippet

Oncolytic viruses (OVs) are immunotherapeutics capable of directly killing cancer cells and with potent immunostimulatory properties. OVs exert their antitumor effect, at least partially, by activating the antitumor immune response, of which NK cells are an important …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system

Similar Documents

Publication Publication Date Title
Marotel et al. The two-faces of NK cells in oncolytic virotherapy
Hodgins et al. Killers 2.0: NK cell therapies at the forefront of cancer control
Walsh et al. Endogenous T cells prevent tumor immune escape following adoptive T cell therapy
JP6678215B2 (en) Targeting CD138 in cancer
Prieto et al. Immunological landscape and immunotherapy of hepatocellular carcinoma
Dianat-Moghadam et al. NK cells-directed therapies target circulating tumor cells and metastasis
Jarosz-Biej et al. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
Lamb et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
ES2716298T3 (en) The tumor microenvironment as a target through the use of manipulated NKT cells
JP2022003043A (en) Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy
US20240325450A1 (en) Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same
US20190175649A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
KR20170117450A (en) Combination of immunotherapy and cytokine regulating therapy for cancer treatment
JP2019524131A (en) Chimeric poxvirus composition and use thereof
JP2017534280A (en) Survivin-specific T cell receptor that targets tumors but does not target T cells
Yang et al. Adoptive cellular therapy (ACT) for cancer treatment
Bhat et al. Emerging role of Natural killer cells in oncolytic virotherapy
US20230312671A1 (en) Grp78 targeted adoptive cell therapy
Zoine et al. Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
Scherwitzl et al. Sindbis virus with anti-OX40 overcomes the immunosuppressive tumor microenvironment of low-immunogenic tumors
Tang et al. The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
AU2020350221A1 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
Bharadwaj et al. Recent Developments in the Immunotherapeutic Approaches for Cancer Treatment
Paquette et al. Combination of radiotherapy and immunotherapy in duality with the protumoral action of radiation